Haemonetics Price Target Raised to $125.00/Share From $115.00 by JMP Securities
Haemonetics Price Target Raised to $125.00/Share From $115.00 by JMP Securities
4 Analysts Assess Haemonetics: What You Need To Know
During the last three months, 4 analysts shared their evaluations of Haemonetics (NYSE:HAE), revealing diverse outlooks from bullish to bearish.The table below provides a concise overview of recent ra
Haemonetics (HAE) Q4 Earnings Top Estimates, Margins Expand
Haemonetics Is Maintained at Outperform by Barrington Research
Haemonetics Is Maintained at Outperform by Barrington Research
Barrington Research: Maintaining the Haemonetics (HAE.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $105.00 to $107.00.
Barrington Research: Maintaining the Haemonetics (HAE.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $105.00 to $107.00.
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $107
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $105 to $107.
Earnings Call Summary | Haemonetics(HAE.US) Q4 2024 Earnings Conference
The following is a summary of the Haemonetics Corporation (HAE) Q4 2024 Earnings Call Transcript:Financial Performance:Haemonetics Corporation saw an organic revenue growth of 10% in Q4 and 12% for th
Needham: Reiterates that Haemonetics (HAE.US) holds the rating.
Needham: Reiterates that Haemonetics (HAE.US) holds the rating.
Needham Reiterates Hold on Haemonetics
Needham analyst Mike Matson reiterates Haemonetics with a Hold.
Haemonetics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 — Needham Reiterates → Hold 04/12/2024 13.39% Barrington Research $105 → $105 Maintains Outper
Strong Buy: Haemonetics Corporation Set for Growth and Margin Expansion
Haemonetics (HAE) Gets a Hold From Needham
Haemonetics Expects 2024 Revenue Growth Of 5%-8% On Reported Basis And 0%-3% On Organic Basis
Haemonetics Expects 2024 Revenue Growth Of 5%-8% On Reported Basis And 0%-3% On Organic Basis
Haemonetics Corp Q4 Profit Decreases, But Beats Estimates
Haemonetics Q4 2024 Adj EPS $0.90 Beats $0.89 Estimate, Sales $343.290M Beat $329.113M Estimate
Haemonetics Q4 2024 Adj EPS $0.90 Beats $0.89 Estimate, Sales $343.290M Beat $329.113M Estimate
Haemonetics 4Q Rev $343M >HAE
Haemonetics 4Q Rev $343M >HAE
Press Release: Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website
Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website PR Newswire BOSTON, May 9, 2024 Financial release accessible online BOSTON, May 9, 2024 /PRNew
Insider Sale at Haemonetics Corp (HAE): EVP, Chief Technology Officer Anila Lingamneni Sells ...
Haemonetics(HAE.US) Officer Sells US$218.98K in Common Stock
$Haemonetics(HAE.US)$ Officer Lingamneni Anila sold 2,305 shares of common stock on May 6, 2024 at an average price of $95 for a total value of $218.98K.Source: Announcement What is statement of chang
Form 144 | Haemonetics(HAE.US) Officer Proposes to Sell 218.98K in Common Stocks
SEC FILLINGS DISCLOSED/ May 6, $Haemonetics(HAE.US)$ Officer Lingamneni Anila intends to sell 2,305 shares of its common stock on May 6, with a total market value of approximately $218.98K. Source:
No Data